-
Roivant Sciences
×
Mild-to-moderate Alzheimer’s Disease
Alzheimer’s disease is the most common form of dementia and the sixth leading cause of death in the United States. A chronic, progressive neurodegenerative disor...
-
Company Overview | Roivant
Company Overview
Why We're Here
Roivant was founded in 2014 with the aim to improve the lives of patients by accelerating the development and commercialization of medici...
-
Our Companies | Roivant
Interested in Joining Us?
Join the team changing the future of healthcare. A career at Roivant is filled with remarkable growth opportunities for those tackling the most significant challenges in scie...
-
Careers | Roivant
Our employees are empowered to be the architects of their own careers.
We are a team of dedicated scientists, development experts, investors, entrepreneurs, and engineers focused on reinventing the wa...
-
Pipeline | Roivant
Pipeline
10
We have run numerous large successful international Phase 3 clinical trials.
Agnostic to therapeutic area and modality
Our pipeline includes innovative product candidates across n...
-
Leadership | Roivant
Chief Executive Officer
Matt Gline serves as Chief Executive Officer of Roivant Sciences. Mr. Gline joined Roivant in March 2016 and previously served as Chief Financial Officer. From April 2014 to Ma...